Budget Impact Analysis of Subcutaneous Infliximab (CT-P13 SC) for Treating Inflammatory Bowel Disease in Saudi Arabia: Analysis from Payer Perspective
Author(s)
Abumansour H1, Alkhatib N2, Almutairi A3, Almadi M4, Halloush S5, Alruthia Y6, Rashdan O7, Al-Shatnawi S8, Azzam N4, Mosli M9, Badawoud A10, Al Yami M11, Alhossan A12, Alharbi I13
1Al-Zaytoonah University, Amman, AM, Jordan, 2Path Economics, LLC, Amman, AM, Jordan, 3Saudi Food and Drug Authority, Riyadh, Riyadh, Saudi Arabia, 4King Saud University Medical City, Riyadh, Riyadh, Saudi Arabia, 5Applied Science Private University, Amman, Amman, Jordan, 6King Saud University, Riyadh, Riyadh, Saudi Arabia, 7Middle East University, Amman, AM, Jordan, 8Jordan University of Science and Technology, Irbid, Irbid, Jordan, 9King Abdulaziz University, Jeddah, Jeddah, Saudi Arabia, 10Princess Nourah bint Abdulrahman University, Riyadh, Riyadh, Saudi Arabia, 11King Saud bin Abdulaziz University, Riyadh, Riyadh, Saudi Arabia, 12King Saud University Medical City, Riyadh, Saudi Arabia, 13King Fahad Armed Forces Hospital, Jeddah, Jeddah, Saudi Arabia
Presentation Documents
OBJECTIVES: The Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV) administration. However, the financial implications of this formulation have not been examined from the perspective of Saudi payers.
METHODS: A prevalence-based budget impact model was developed to evaluate the financial effects of introducing "environment without" versus "with infliximab SC." The model's time horizon spanned over 2 years (2021-2023), aligning with the biennial national pharmaceutical procurement cycle. The comparison focused on infliximab SC versus all available formulations of infliximab IV in the Saudi market for two inflammatory bowel diseases (IBD): Ulcerative Colitis (UC) and Crohn’s Disease (CD). Treatment comparators' comparability and dose escalations were substantiated by published studies, utilizing dosing information from the summary of product characteristics. Drug acquisition costs were derived from SFDA registered prices, with IV formulation administration costs included. Scenario analysis assessed the budget impact of infliximab SC introduction at uptake rates ranging from 0% to 100%.
RESULTS: Introducing infliximab SC demonstrated cost-saving potential in the treatment of IBD. At 100% uptake with UC patients for 2 years, infliximab SC resulted in savings of -SAR-31.9 million (-SAR29,145 per patient). Similarly, for CD, introducing infliximab SC at 100% uptake over 2 years yielded savings of -SAR106.2 million (-SAR36,585 per patient)
CONCLUSIONS: This study reveals that infliximab SC is associated with cost-saving potential when compared to infliximab IV formulations available in Saudi Arabia. Future research should address uncertainties related to real-world comparative effectiveness, the convenience of administration, patient tolerability, and physician acceptance of the SC formulation of infliximab, alongside comparisons with other TNF-alpha inhibitors.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
EE411
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Thresholds & Opportunity Cost
Disease
Biologics & Biosimilars, Gastrointestinal Disorders